ClearPoint Neuro, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ClearPoint Neuro, Inc. (CLPT) on September 14, 2020. The filing discloses significant changes in executive leadership, specifically the departure of the Chief Financial Officer (CFO) and the appointment of a successor.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements and employment terms.
Material Changes
- Departure of CFO: Harold A. Hurwitz is voluntarily resigning as Chief Financial Officer, effective December 31, 2020. The resignation is not due to any disagreement with management.
- Appointment of New CFO: Danilo D'Alessandro has been appointed to succeed Mr. Hurwitz. He will initially serve as Vice President, Finance starting September 29, 2020, and will assume the role of CFO effective January 1, 2021.
- Compensation for Departing CFO: Mr. Hurwitz will receive his annual bonus (subject to performance), 50% of his current base salary as a lump sum, and $10,000 per month for consulting services during a 12-month transition period. All unvested stock options and restricted stock will be fully accelerated.
- Compensation for Incoming CFO: Mr. D'Alessandro's base salary is $285,000 with a target annual bonus of 35%. He received a $50,000 signing bonus (split between cash and stock) and was granted options for 75,000 shares and 30,000 restricted shares, vesting over three years.
Outlook, Risks, and Contingencies
The filing outlines standard severance and change-of-control provisions for the new CFO. In the event of termination without cause or for good reason, Mr. D'Alessandro is entitled to one year of base salary, average bonus, and full acceleration of equity. In a change-of-control scenario followed by termination without cause, severance increases to two times base salary and two times the average bonus. The filing notes that Mr. D'Alessandro is subject to non-compete and non-solicitation covenants.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price for the 75,000 stock options and 30,000 restricted shares granted to Mr. D'Alessandro.
- Confirm the total cash outflow for Mr. Hurwitz's transition package, including the variable annual bonus component.
- Review the full text of the Transition Agreement (Exhibit 10.1) and Employment Agreement (Exhibit 10.2) for specific performance metrics tied to bonuses.
- Monitor the transition timeline to ensure Mr. D'Alessandro assumes the CFO role by January 1, 2021, as scheduled.